Latest & greatest articles for adhd

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on adhd or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on adhd and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

ADHD

ADHD (or Attention deficit hyperactivity disorder) is a neurodevelopmental type mental disorder. It is characterised two main categories of two types of behavioural problems:

  • inattentiveness
  • hyperactivity and impulsiveness

Most people with ADHD have problems that fall into both categories, but it doesn’t have to be the case. If a person just has inattentiveness it is referred to as attention deficit disorder (ADD).

Methylphenidate is a commonly used medication used to treat patients suffering from attention-deficit hyperactivity disorder. Methylphenidate is part of a group of drugs known as stimulants. Central nervous system stimulants help change the amounts of natural substances in the brain. But it is not the only intervention; others include Bupropion, exercise and CBT (Cognitive behavioural therapy).

Extensive ADHD research and case studies have been carried out over numerous years. Trip has unrivalled coverage of the evidence base including systematic reviews, clinical trials, clinical guidelines and case studies.

Studies are ongoing to assess the safety and effectiveness of stimulants used on children with ADHD and intellectual disabilities as well as in other populations and other interventions. Trip also includes ongoing controlled trials and ongoing systematic reviews (via the PROSPERO database).

Top results for adhd

121. Blood pressure and heart rate over 10 years in the multimodal treatment study of children with ADHD Full Text available with Trip Pro

Blood pressure and heart rate over 10 years in the multimodal treatment study of children with ADHD It is unknown whether prolonged childhood exposure to stimulant medication for the treatment of attention deficit hyperactivity disorder (ADHD) increases the risk for developing abnormalities in blood pressure or heart rate. The authors examined the association between stimulant medication and blood pressure and heart rate over 10 years.A total of 579 children, ages 7–9, were randomly assigned (...) to 14 months of medication treatment, behavioral therapy, the combination of the two, or usual community treatment. The controlled trial was followed by naturalistic treatment with periodic assessments. Blood pressure and heart rate data were first analyzed with linear regression models based on an intent-to-treat approach, using raw data and the blood pressure categories of prehypertension and hypertension. Currently medicated patients were then compared with never or previously medicated patients

2012 EvidenceUpdates Controlled trial quality: uncertain

122. Parent Training Interventions for Attention Deficity Hyperactivity Disorder (ADHD) in Children Aged 5 to 18 years Full Text available with Trip Pro

behaviour or wellbeing (ADHD‐related or not). 3.1.2 Types of participants Children and young people aged five to 18 years (or with a mean age above five years) in whom the main problem was ADHD (or hyperkinetic disorder) diagnosed using DSM or ICD operationalised diagnostic criteria. The diagnoses must have been clinical diagnoses by specialists with or without the use of semi‐structured or structured interview instruments. Acceptable diagnoses included: • AttentionDeficit/Hyperactivity Disorder (DSM (...) Parent Training Interventions for Attention Deficity Hyperactivity Disorder (ADHD) in Children Aged 5 to 18 years Parent Training Interventions for Attention Deficity Hyperactivity Disorder (ADHD) in Children Aged 5 to 18 years - Zwi - 2012 - Campbell Systematic Reviews - Wiley Online Library By continuing to browse this site, you agree to its use of cookies as described in our . Search within Search term Search term SYSTEMATIC REVIEW Open Access Parent Training Interventions for Attention

2012 Campbell Collaboration

123. Atomoxetine reduces ADHD symptoms in children with autism spectrum disorder

atomoxetine reduce symptoms of attention deficit/hyperactivity (ADHD) disorder in children with autism spectrum disorder (ASD) compared with placebo? Patients: Ninety-seven children and adolescents aged between 6 and 17 years with a clinical diagnosis of ASD (confirmed using the Autism Diagnostic Interview revised) and concomitant ADHD symptoms (according to DSM-IV-TR criteria, confirmed using the ADHD Rating Scale, ADHD-RS). Exclusions: psychosis, bipolar disorder, substance abuse, serious medical (...) Atomoxetine reduces ADHD symptoms in children with autism spectrum disorder Atomoxetine reduces ADHD symptoms in children with autism spectrum disorder | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts

2012 Evidence-Based Mental Health

124. Review: methylphenidate and atomoxetine have similar efficacy and acceptability in children and adolescents with ADHD

: methylphenidate and atomoxetine have similar efficacy and acceptability in children and adolescents with ADHD Statistics from Altmetric.com Question Question: Is methylphenidate (MPH) or atomoxetine superior to the treatment of children and adolescents with attention deficit hyperactivity disorder (ADHD)? Outcomes: Symptoms (assessed on the ADHDRS-IV Parent: Inv and Turgay DSM-IV-Based Child and Adolescent Behaviour Disorders Screening and Rating Scale (T-DSM-IV-S)); response (as defined in the individual (...) Review: methylphenidate and atomoxetine have similar efficacy and acceptability in children and adolescents with ADHD Review: methylphenidate and atomoxetine have similar efficacy and acceptability in children and adolescents with ADHD | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your

2012 Evidence-Based Mental Health

125. Review: insufficient evidence available on parent training programmes for ADHD in children

from Altmetric.com Question Question: Do parent training programmes reduce symptoms and associated problems in children with attention-deficit hyperactivity disorder (ADHD)? Outcomes: Primary outcomes: changes in the child's ADHD symptom-related behaviour at home and school; changes in the child's general behaviour. Methods Design: Systematic review and meta-analysis. Data sources: CENTRAL (2010, Issue 3), MEDLINE, EMBASE, CINAHL, PsycINFO, Dissertation Abstracts International and the metaRegister (...) on children's own behaviour or well-being were excluded. Participants were aged 5–18 years and their main problem had to be clinically diagnosed with ADHD or hyperkinetic disorder according to DSM or ICD operationalised criteria. Main results Five trials (284 participants) met inclusion … Request Permissions If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant

2012 Evidence-Based Mental Health

126. Stimulant treatment in healthy young people with ADHD is not associated with increased risk of cardiovascular events

treatment in healthy young people with ADHD is not associated with increased risk of cardiovascular events Statistics from Altmetric.com Question Question: Is stimulant treatment associated with an increased risk of cardiovascular events in young people with attention deficit hyperactive disorder (ADHD)? People: 171 126 youths between the age of 6 and 21 years without known cardiovascular risk factors, who had ADHD and were enrolled in a health plan with pharmacy coverage. Participants were those who (...) had an initial first or second listed service claim for ADHD (ICD-9 code 314) after a period of eligibility of at least 180 days without an ADHD medical claim diagnosis and without any prescriptions for stimulants. Individuals were excluded if they had received a diagnosis of any of a list of ‘high-risk exclusion conditions’ or ‘high-risk censored events’ during the 180-day eligibility period. These conditions and events related to underlying general medical disorders that might increase risk

2012 Evidence-Based Mental Health

127. [Efficacy of atomoxetine and methylphenidate in attention deficits hyperactivity disorder in adults: a rapid review]

these two medications for adult ADHD is considered appropriate. Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Adrenergic Uptake Inhibitors; Adult; Attention Deficit Disorder with Hyperactivitys; Methylphenidate; Propylamines Language Published Korean Country of organisation South Korea English summary An English language summary is available. Address for correspondence National Evidence-based Healthcare Collaborating Agency (NECA), Changkyung B/D 9F, Wonnam-dong 28-7 (...) [Efficacy of atomoxetine and methylphenidate in attention deficits hyperactivity disorder in adults: a rapid review] [Efficacy of atomoxetine and methylphenidate in attention deficits hyperactivity disorder in adults: a rapid review] [Efficacy of atomoxetine and methylphenidate in attention deficits hyperactivity disorder in adults: a rapid review] Jang BH, Lee HY, Jung YJ, An JH Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA

2012 Health Technology Assessment (HTA) Database.

128. Cost effectiveness of guanfacine extended-release versus atomoxetine for the treatment of attention-deficit/hyperactivity disorder: application of a matching-adjusted indirect comparison Full Text available with Trip Pro

-effectiveness of guanfacine extended-release (GXR) versus atomoxetine for the treatment of ADHD (attention-deficit/hyperactivity disorder) in children and adolescents. The authors concluded that GXR was cost-effective compared to atomoxetine. The study methods seemed appropriate and were reported clearly and transparently. The authors' conclusions appear to be appropriate. Type of economic evaluation Cost-utility analysis Study objective The study objective was to assess the cost-effectiveness of guanfacine (...) extended-release (GXR) versus atomoxetine for the treatment of attention-deficit/hyperactivity disorder (ADHD) in children and adolescents. Interventions Two interventions were compared in the cost-effectiveness analysis: guanfacine extended release (GXR) and atomoxetine. The effectiveness analysis also considered three dosage strategies for GXR: 0.09 to 0.12mg/kg/day; 0.075 to 0.09mg/kg/day; and 0.046 to 0.075mg/kg/day. One atomoxetine dosage strategy was considered: 1.2mg/kg/day. Location/setting USA

2012 NHS Economic Evaluation Database.

129. Use of ADHD drugs in children and young adults does not increase risk of serious cardiovascular adverse events compared with non-use

with non-use Article Text Prognosis Use of ADHD drugs in children and young adults does not increase risk of serious cardiovascular adverse events compared with non-use Statistics from Altmetric.com Question Question Are children and young adults using attention deficit hyperactivity disorder (ADHD) medication are at increased risk for serious cardiovascular adverse events? People 1 200 438 children and young people (aged 2–24 years; mean age 11.1 years at baseline). Patients with congenital heart (...) Use of ADHD drugs in children and young adults does not increase risk of serious cardiovascular adverse events compared with non-use Use of ADHD drugs in children and young adults does not increase risk of serious cardiovascular adverse events compared with non-use | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please

2012 Evidence-Based Mental Health

130. Parental ADHD affects parent and child outcomes of parental friendship coaching

Question Does parental attention-deficit/hyperactivity disorder (ADHD) predict child and parent outcomes of parental friendship coaching? Population 62 children (6–10 years old) with confirmed diagnoses of ADHD and one parent for each of the children. Children with a pervasive developmental disorder, full Scale IQ<70 or verbal IQ<75 were excluded. Participants had taken part in a randomised controlled trial comparing parental friendship coaching versus control (no coaching). Parental friendship (...) coaching was a parent training intervention aimed at improving the children's friendship skills. The participating families were recruited from local schools, clinics and paediatrics offices. Setting USA; time period not stated. Prognostic factors Parental ADHD symptoms and parent-child interactions. The parents completed an 18-item Current Symptoms Scale to provide a measure of ADHD symptoms (inattention, impulsivity and hyperactivity) at baseline. Parent-child interactions were observed in laboratory

2012 Evidence-Based Mental Health

131. ADHD is associated with an increased risk of written-language disorder

-language disorder (WLD), with and without reading disability (RD), among children with and without attention-deficit/hyperactivity disorder (ADHD)? Population 5699 children born between 1st January 1976 and 31st December 1982 in one school district, who still lived in the area after age 5 years, and who did not have clinical diagnoses of severe intellectual disability or full-scale IQ scores <50. Setting Rochester, Minnesota, USA; participants born from 1976 to 1982. Assessment Children were assessed (...) ADHD is associated with an increased risk of written-language disorder ADHD is associated with an increased risk of written-language disorder | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username

2012 Evidence-Based Mental Health

132. The Strengths and Difficulties Questionnaire hyperactivity-inattention subscale is more sensitive for the ADHD-combined subtype than other subtypes in 7?9-year-old school children

algorithm a valid screening tool for attention deficit hyperactivity disorder (ADHD) phenotype in Norwegian school children? Patients 6233 children (7–9 years old). Questionnaires were sent to teachers and parents of all 9137 children enrolled in second through fourth grades in Bergen, Norway during 2002. Setting Public, private and special education schools in Bergen, Norway; 2002. Test SDQ hyperactivity-inattention subscale, reported by both teachers and parents. The SDQ is a 25 item broad-band (...) The Strengths and Difficulties Questionnaire hyperactivity-inattention subscale is more sensitive for the ADHD-combined subtype than other subtypes in 7?9-year-old school children The Strengths and Difficulties Questionnaire hyperactivity-inattention subscale is more sensitive for the ADHD-combined subtype than other subtypes in 7–9-year-old school children | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your

2012 Evidence-Based Mental Health

133. Guidelines and recommendations for ADHD in children and adolescents

-commercial purposes only and provided appropriate credit is given to CADTH. PREPARED BY: Canadian Agency for Drugs and Technologies in Health Tel: 1-866-898-8439 www.cadth.ca Guidelines and Recommendations for ADHD in Children and Adolescents i EXECUTIVE SUMMARY Issue Medications to treat attention-deficit/hyperactivity disorder (ADHD) in children and adolescents are available in short- and long-acting formulations. Short-acting formulations of methylphenidate (e.g., Ritalin) and dextroamphetamine (e.g (...) presented in this summary report reveals substantial use of health care budgets to reimburse long-acting formulations. In 2010, expenditures on long-acting medications had exceeded $35 million (or 77% of total expenditures on ADHD medications) by public drug plans in Canada. Guidelines and Recommendations for ADHD in Children and Adolescents ii ABBREVIATIONS AACAP American Academy of Child & Adolescent Psychiatry ADHD attention-deficit/hyperactivity disorder ADHD/HKD attention-deficit and hyperkinetic

2012 CPG Infobase

134. Pharmacological and non-pharmacological therapies for adults with attention-deficit/hyperactivity disorder: systematic review and meta-analysis of clinical evidence

Pharmacological and non-pharmacological therapies for adults with attention-deficit/hyperactivity disorder: systematic review and meta-analysis of clinical evidence Pharmacological and non-pharmacological therapies for adults with attention-deficit/hyperactivity disorder: systematic review and meta-analysis of clinical evidence Pharmacological and non-pharmacological therapies for adults with attention-deficit/hyperactivity disorder: systematic review and meta-analysis of clinical evidence (...) Canadian Agency for Drugs and Technologies in Health Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Canadian Agency for Drugs and Technologies in Health. Pharmacological and non-pharmacological therapies for adults with attention-deficit/hyperactivity disorder: systematic review and meta-analysis of clinical evidence. Ottawa: Canadian Agency

2011 Health Technology Assessment (HTA) Database.

135. Long versus short acting drugs for attention deficit/hyperactivity disorder in children and adolescents: a review of the guidelines and recommendations

' conclusions Although evidence-based recommendations support the use of stimulants as first line therapy when treating children with ADHD, the recommendation to use long acting formulations over short acting is based on expert opinion. Considerations include patient preference, convenience, compliance, reducing stigma, and the potential for drug diversion. Project page URL Indexing Status Subject indexing assigned by CRD MeSH Attention Deficit Disorder with Hyperactivity /drug therapy; Delayed-Action (...) Long versus short acting drugs for attention deficit/hyperactivity disorder in children and adolescents: a review of the guidelines and recommendations Long versus short acting drugs for attention deficit/hyperactivity disorder in children and adolescents: a review of the guidelines and recommendations Long versus short acting drugs for attention deficit/hyperactivity disorder in children and adolescents: a review of the guidelines and recommendations Canadian Agency for Drugs and Technologies

2011 Health Technology Assessment (HTA) Database.

136. Quality assessment of the Canadian attention deficit hyperactivity disorder resource alliance ADHD practice guidelines in adults with ADHD

Quality assessment of the Canadian attention deficit hyperactivity disorder resource alliance ADHD practice guidelines in adults with ADHD Quality assessment of the Canadian attention deficit hyperactivity disorder resource alliance ADHD practice guidelines in adults with ADHD Quality assessment of the Canadian attention deficit hyperactivity disorder resource alliance ADHD practice guidelines in adults with ADHD Canadian Agency for Drugs and Technologies in Health Record Status (...) This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Canadian Agency for Drugs and Technologies in Health. Quality assessment of the Canadian attention deficit hyperactivity disorder resource alliance ADHD practice guidelines in adults with ADHD. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). 2011 Authors' conclusions The CADDRA ADHD practice guidelines

2011 Health Technology Assessment (HTA) Database.

137. Quality assessment of the canadian attention deficit hyperactivity disorder resource alliance ADHD practice guidelines for children, adolescents and adults with ADHD

Quality assessment of the canadian attention deficit hyperactivity disorder resource alliance ADHD practice guidelines for children, adolescents and adults with ADHD Quality assessment of the Canadian attention deficit hyperactivity disorder resource alliance ADHD practice guidelines for children, adolescents and adults with ADHD Quality assessment of the Canadian attention deficit hyperactivity disorder resource alliance ADHD practice guidelines for children, adolescents and adults with ADHD (...) Canadian Agency for Drugs and Technologies in Health Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Canadian Agency for Drugs and Technologies in Health. Quality assessment of the Canadian attention deficit hyperactivity disorder resource alliance ADHD practice guidelines for children, adolescents and adults with ADHD. Ottawa: Canadian Agency

2011 Health Technology Assessment (HTA) Database.

138. Cognitive-behavioral therapy for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in adults

Cognitive-behavioral therapy for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in adults Cognitive-behavioral therapy for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in adults Cognitive-behavioral therapy for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in adults Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database (...) . Citation Cognitive-behavioral therapy for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in adults. Lansdale: HAYES, Inc.. Directory Publication. 2011 Authors' objectives Cognitive-behavioral therapies (CBT) are psychological treatments composed of educational, behavioral, and cognitive elements. The goal of CBT for ADHD is to reduce the severity of ADHD symptoms, reduce ADHD-related comorbidities, and improve adaptive functioning in areas of daily living and self-esteem. Therapies

2011 Health Technology Assessment (HTA) Database.

139. Acupuncture for Attention Deficit Hyperactivity Disorder (ADHD) in children and adolescents. (Abstract)

Acupuncture for Attention Deficit Hyperactivity Disorder (ADHD) in children and adolescents. Attention Deficit Hyperactivity Disorder (ADHD) is a common childhood psychiatric disorder with features of inattention, hyperactivity and impulsivity. There is increasing interest in complementary and alternative therapies such as acupuncture; however, it remains unclear whether the use of acupuncture in children and adolescents with ADHD is supported by the existing evidence.To assess the efficacy (...) and safety of acupuncture as a treatment for ADHD in children and adolescents.We searched CENTRAL (The Cochrane Library 2010, Issue 2); MEDLINE (21 May 2010); CINAHL (21 May 2010); EMBASE (21 May 2010); ERIC (21 May 2010); PsycINFO (21 May 2010), Chinese Biological Medicine Database (10 May 2010); Chinese Scientific Periodical Database of VIP INFORMATION (10 May 2010); China Periodical in China National Knowledge Infrastructure (10 May 2010); and Chinese Evidence-Based Medicine Database (10 May 2010). We

2011 Cochrane

140. Pharmacological treatment for Attention Deficit Hyperactivity Disorder (ADHD) in children with comorbid tic disorders. Full Text available with Trip Pro

Pharmacological treatment for Attention Deficit Hyperactivity Disorder (ADHD) in children with comorbid tic disorders. Attention Deficit Hyperactivity Disorder (ADHD) is the most prevalent of the comorbid psychiatric disorders that complicate tic disorders. Medications commonly used to treat ADHD symptoms include the stimulants methylphenidate and amphetamine; nonstimulants, such as atomoxetine; tricyclic antidepressants; and alpha agonists. Due to the impact of ADHD symptoms on the child (...) with tic disorder, treatment of ADHD is often of greater priority than the medical management of tics. However, for many decades clinicians have been reluctant to use stimulants to treat children with ADHD and tics for fear of worsening their tics. To assess the effects of pharmacological treatments for ADHD on ADHD symptoms and tic severity in children with ADHD and comorbid tic disorders. We searched CENTRAL (The Cochrane Library 2009, Issue 4), MEDLINE (1950 to July 2009), EMBASE (1980 to July 2009

2011 Cochrane